We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.3M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$595K
2
AMRN
Amarin Corp
AMRN
+$297K
3
UTHR icon
United Therapeutics
UTHR
+$282K
4
ALKS icon
Alkermes
ALKS
+$253K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$64.5K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$868K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$813K
3
BLUE
bluebird bio
BLUE
+$743K
4
INSM icon
Insmed
INSM
+$690K
5
PCRX icon
Pacira BioSciences
PCRX
+$489K

Sector Composition

Rank Sector Weight
1 Healthcare 54.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
51
Exelixis
EXEL
$14.1B
$232K 0.42%
13,132
+1,692
+15% +$34.2K
ALKS icon
52
Alkermes
ALKS
$8.79B
$227K 0.41%
+11,632
New +$253K
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$2.88B
$217K 0.39%
5,064
– –
KYNB
54
Kyntra Bio
KYNB
$29.3M
$212K 0.38%
230
+35
+18% +$38.4K
SCTL
55
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$126K 0.23%
12,659
– –
AGIO icon
56
Agios Pharmaceuticals
AGIO
$2.36B
– –
-4,806
Closed -$240K
ANAB icon
57
AnaptysBio
ANAB
$1.72B
– –
-6,116
Closed -$345K
BLUE
58
DELISTED
bluebird bio
BLUE
– –
-451
Closed -$743K
FOLD
59
DELISTED
Amicus Therapeutics
FOLD
– –
-36,731
Closed -$458K
INSM icon
60
Insmed
INSM
$23.5B
– –
-26,936
Closed -$690K
MDGL icon
61
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-3,570
Closed -$374K
PCRX icon
62
Pacira BioSciences
PCRX
$1.01B
– –
-11,250
Closed -$489K
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.82B
– –
-5,353
Closed -$813K
VKTX icon
64
Viking Therapeutics
VKTX
$4.31B
– –
-48,485
Closed -$402K
IMMU
65
DELISTED
Immunomedics Inc
IMMU
– –
-62,575
Closed -$868K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 56% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.